QGE031
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
Allergic AsthmaAllergyAsthmaAtopic DermatitisBullous PemphigoidChronic Spontaneous UrticariaFood allergyPeanut Allergy
Phase 1
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects
CompletedNCT01596712
Start: 2011-03-31End: 2012-08-31Updated: 2012-11-22
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
CompletedNCT01703312
Start: 2012-11-30End: 2013-10-31Updated: 2016-04-20
Phase 2
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
WithdrawnNCT01451450
Updated: 2012-07-23
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
CompletedNCT01552629
Start: 2012-01-05End: 2013-08-28Updated: 2017-02-23
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
TerminatedNCT01688882
Start: 2013-01-31End: 2015-03-31Updated: 2016-04-28
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
CompletedNCT01716754
Start: 2012-12-31End: 2016-01-31Updated: 2017-08-11
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
TerminatedNCT02075008
Start: 2014-03-27End: 2016-03-22Updated: 2017-08-11
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
TerminatedNCT02336425
Start: 2015-09-30End: 2016-03-31Updated: 2017-08-11
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
CompletedNCT02477332
Start: 2015-07-15End: 2017-06-12Updated: 2021-01-05